BMI View: Despite growing in recent years, the absolute value of the Estonian pharmaceutical market
remains small and will continue to remain a marginal market in the Central and Eastern European region.
Low-cost generic drugs are prevalent in the market, with doctors obliged t ..."
BMI View: Despite the French government partially abandoning fiscal deficit targets in its 2015 budget,
cost-containment measures will continue to weigh on the pharmaceuticals and healthcare sector for the
foreseeable future. The government's strategy of emphasising preventive ..."
BMI View: The Swiss government will need to develop policies to maintain the country's long-term
attractiveness as a site for clinical trials, especially as we expect cost of conducting clinical research to
rise. The drivers of increased attractiveness of non-traditional locati ..."
BMI View: Austria's economy is set to grow at a faster clip in the second half of 2014 and domestic
consumer demand is poised to strengthen in this period. We have revised the healthcare and
pharmaceutical market forecast slightly upwards to reflect this. The EUR-USD ..."
BMI View: The Ministry of Health's plan to increase MAH fees, coupled with price cuts for generic drugs
and freezes on OTC medicine prices indicate that the Bulgarian pharmaceutical market will not see
meaningful growth in 2014. However, we expect a pickup in demand f ..."
BMI View: Germany's medicines pricing regime will continue to restrict drugmakers' revenue streams. The
AMNOG has proved to be tough, with the majority of medicine reimbursement prices lying under the
average of or below the lowest of the European reference country ba ..."
BMI View: Polish pharmacies reported flat year-on-year growth in Q114 sales data. However, BMI expect
growth to pick up in the remaining quarters of the year as the country's exports increase and household
consumption rises. We highlight consumer healthcare products, ..."
BMI View: Our above-consensus outlook for economic growth in Romania has borne out, with positive
implications for the pharmaceutical sector. With wages set to rise and consumer spending continuing to
grow at a rapid clip, consumer non-discretionary spending is set to ..."
? BMI View: Political instability caused by the collapse of the coalition government and the resignation by
the prime minister has increased the risk of a slowdown in GDP growth and a likely loss of momentum in
structural reforms. Therefore, the burden of healthcare c ..."
BMI View: The drop in SSN pharmaceutical expenditure in 9M13 serves as a warning for the continuation
of a fall in spending on medicines for the rest of the year. Our bearish outlook takes into account the
government's aim to slash public healthcare costs - hitting drug compani ..."